Atlas Trials

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Clinical trial NCT01465386 · TERMINATED

Trial details

NCT number
NCT01465386
Sponsor
Fred Hutchinson Cancer Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Promyelocytic Leukemia (M3)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid Leukemia
Start date
2011-11-01
Primary completion
2014-01-28
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.